Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 4,710,000 shares, a growth of 1,022.5% from the December 31st total of 419,600 shares. Based on an average daily trading volume, of 6,840,000 shares, the short-interest ratio is presently 0.7 days.

Institutional Trading of Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP raised its position in Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) by 359.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 328,533 shares of the company's stock after purchasing an additional 256,967 shares during the period. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. 44.02% of the stock is currently owned by institutional investors.

Vincerx Pharma Stock Down 5.5 %

VINC traded down $0.09 on Wednesday, hitting $1.56. The company's stock had a trading volume of 18,056,834 shares, compared to its average volume of 1,231,417. The company's 50 day simple moving average is $4.09 and its 200-day simple moving average is $8.90. Vincerx Pharma has a 12 month low of $1.45 and a 12 month high of $187.44. The firm has a market cap of $52.49 million, a P/E ratio of -1.51 and a beta of 1.48.

Analysts Set New Price Targets

Separately, Leerink Partners decreased their price target on shares of Vincerx Pharma from $80.00 to $40.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.